Analyst Price Target is GBX 0
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for C4X Discovery in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 16.70.
Current Consensus is
The current consensus among 1 contributing investment analysts is to buy stock in C4X Discovery. This Buy consensus rating has held steady for over two years.
C4X Discovery Holdings plc operates as drug discovery company in the United Kingdom. The company provides Taxonomy3, a novel in silico platform technology that utilizes proprietary mathematical algorithms to perform complex multivariate analysis of genetic data; Conformetrix, a technology platform which allows 3D-shapes of free drug molecules to be measured from experimental data, giving medicinal chemists new and unprecedented insights into the behavior and physical properties of drug molecules; and 4Sight for visualizing 4D molecules in virtual reality research scientists to view, understand and interrogate the complex, multidimensional molecular shape data of drug molecules. Its product pipeline includes Orexin-1, a receptor antagonist for the treatment of addictive disorders; NRF-2 activator to treat various inflammatory diseases; IL-17A inhibitor for inflammation and autoimmune diseases; a4ß7 integrin inhibitors for the treatment of inflammatory bowel disease; and MALT-1 inhibitors to treat hematological cancer. It has partnerships with Sanofi, therapeutics, horizon, LifeArc, INDIVIOR, and Phoremost. The company was formerly known as Schosween 24 plc and changed its name to C4X Discovery Holdings plc October 2014. The company was incorporated in 2007 and is based in Manchester, the United Kingdom.